1) 日本整形外科学会骨軟部腫瘍委員会. 全国骨腫瘍登録一覧表(令和元年度)2019.
2) Gurney JG, Swensen AR, Bulterys M. Malignant Bone Tumors. In: Ries LAG, Smith MA, Gurney JG, Linet M, Tamra T, Young JL, et al., editors. Cancer Incidence and Survival among Children and Adolescents: United States SEER Program 1975-1999, National Cancer Institute, SEER Program. Bethesda: NIH Pub.1999.
3) Unni KK, Inwards CY, Bridge JA, Kindblom LG, Wold LE. Osteosarcoma of Bone. In. Tumors of the Bones and Joints (AFIP Atlas of Tumor Pathology, Fourth Series, Fascicle 2). Silver Spring, Mayland: ARP PRESS; 2005:135-192.
4) 柴佳奈子,種市洋, 骨肉腫の治療の現状. Dokkyo Journal of Medical Sciences.2019; 46(3): 187-192.
5) Fuchs N, Winkler K, Osteosarcoma, Curr Opin Oncol. 1993; 5(4): 667-671.
6) Kager L, Zoubek A, Potschger U, Kastner U, Flege S, Kempf-Bielack B, et al. Primary metastatic osteosarcoma: presentation and outcome of patients treated on neoadjuvant Cooperative Osteosarcoma Study Group protocols. J Clin Oncol. 2003; 21(10):2011-2018.
7) Hegyi M, Semsei AF, Jakab Z, Antal I, Kiss J, Szendroi M, Csoka M and Kovacs G: Good prognosis of localized osteosarcoma in young patients treated with limb-salvage surgery and chemotherapy. Pediatr Blood Cancer. 2011 ; 57(3): 415–422.
8) Isacoff WH, Eilber F, Tabbarah H, Klein P, Dollinger M, Lemkin S, et al. Cancer Treat Rep. 1978 ; 62(9): 1295-1304.
9) Howard SC, McCormick J, Pui CH, Buddington RK and Harvey RD: Preventing and managing toxicities of high-dose methotrexate. Oncologist. 2016; 21(12): 1471-1482.
10) ファイザー株式会社. メソトレキセート®点滴静注液 1,000mg インタビューフォー ム.第 19 版, 2020 年 12 月改定
11) Meyers PA, Schwartz CL, Krailo M, Kleinerman ES, Betcher D, Bernstein ML, et al. Osteosarcoma: a randomized, prospective trial of the addition of ifosfamide and/or muramyl tripeptide to cisplatin, doxorubicin, and high-dose methotrexate. J Clin Oncol. 2005; 23(9): 2004-2011.
12) Baum ES, Gaynon P, Greenberg L, Krivit W, Hammond D. Phase II study of cis- dichlorodiammineplatinum(II) in childhood osteosarcoma: Children's Cancer Study Group Report. Cancer Treat Rep. 1979; 63(9-10):1621-1627.
13) Iwamoto Y, Tanaka K, Isu K, Kawai A, Tatezaki S, Ishii T, et al. Multiinstitutional phase II study of neoadjuvant chemotherapy for osteosarcoma (NECO study) in Japan: NECO-93J and NECO-95J. J Orthop Sci. 2009; 14(4): 397-404.
14) Holmboe L, Andersen AM, Mørkrid L, Slørdal L and Hall KS: High dose methotrexate chemotherapy: pharmacokinetics, folate and toxicity in osteosarcoma patients. Br J Clin Pharmacol. 2012; 73(1): 106-114.
15) Cheng KK: Association of plasma methotrexate, neutropenia, hepatic dysfunction, nausea/vomiting and oral mucositis in children with cancer. Eur J Cancer Care (Engl). 2008; 17(3):306-311.
16) Weber BL, Tanyer G, Poplack DG, Reaman GH, Feusner JH, Miser JS and Bleyer WA: Transient acute hepatotoxicity of high-dose methotrexate therapy during childhood. NCI Monogr. 1987; (5): 207-212.
17) Hegyi M, Gulácsi A, Cságoly E, Csordás K, Eipel OT, Erdélyi DJ, Müller J, Nemes K, Lautner-Csorba O and Kovács GT: Clinical relations of methotrexate pharmacokinetics in the treatment for pediatric osteosarcoma. Toxicol Sci. 2014; 142(1): 45–55.
18) Bath RK, Brar NK, Forouhar FA and Wu GY: A review of methotrexate-associated hepatotoxicity. J Dig Dis. 2014; 15(10): 517- 524.
19) Nyfors A: Liver biopsies from psoriatics related to methotrexate therapy. 3. Findings in post-methotrexate liver biopsies from 160 psoriatics. Acta Pathol Microbiol Scand A. 1997; 85(4): 511-518.
20) Watson WA, Litovitz TL, Rodgers Jr GC, Klein-Schwartz W, Reid N, Youniss J, Flanagan A, Wruk KM: 2004 Annual report of the American Association of Poison Control Centers Toxic Exposure Surveillance System. Am J Emerg Med. 2005; 23(5): 589-666..
21) Kremer JM, Alarcón GS, Lightfoot Jr RW, Willkens RF, Furst DE, Williams HJ, Dent PB and Weinblatt ME: Methotrexate for rheumatoid arthritis. Suggested guidelines for monitoring liver toxcity. American College of Rheumatology. Arthritis Rheum. 1994; 37(3): 316-328.
22) Li JY, Cao HY, Liu P, Cheng GH and Sun MY: Glycyrrhizic acid in the treatment of liver diseases: literature review. Biomed Res Int. 2014; 2014: 872139.
23) Kiso Y, Tohkin M, Hikino H, Hattori M, Sakamoto T and Namba T: Mechanism of antihepatotoxic activity of glycyrrhizin. I: Effect on free radical generation and lipid peroxidation. Planta Med. 1984; 50(4): 298-302.
24) Deng S, May BH, Zhang AL, Lu C and Xue CC: Topical herbal medicine combined with pharmacotherapy for psoriasis: a systematic review and meta-analysis. Arch Dermatol Res. 2013; 305(3): 179-189.
25) Lin SP, Tsai SY, Hou YC and Chao PD: Glycyrrhizin and licorice significantly affect the pharmacokinetics of methotrexate in rats. J Agric Food Chem. 2009; 57(5): 1854-1859.
26) Marina NM, Smeland S, Bielack SS, Bernstein M, Jovic G, Krailo MD, Hook JM, Arndt C, van den Berg H, Brennan B, Brichard B, Brown KLB, Butterfass-Bahloul T, Calaminus G, Daldrup-Link HE, Eriksson M, Gebhardt MC, Gelderblom H, Gerss J, Goldsby R, Goorin A, Gorlick R, Grier HE, Hale JP, Hall KS, Hardes J, Hawkins DS, Helmke K, Hogendoorn PCW, Isakoff MS, Janeway KA, Jürgens H, Kager L, Kühne T, Lau CC, Leavey PJ, Lessnick SL, Mascarenhas L, Meyers PA, Mottl H, Nathrath M, Papai Z, Randall RL, Reichardt P, Renard M, Safwat AA, Schwartz CL, Stevens MCG, Strauss SJ, Teot L, Werner M, Sydes MR and Whelan JS: Comparison of MAPIE versus MAP in patients with a poor response to preoperative chemotherapy for newly diagnosed high-grade osteosarcoma (EURAMOS-1): an open-label, international, randomised controlled trial. Lancet Oncol. 2016; 17(10): 1396- 1408.
27) Buuren SV, Groothuis-Oudshoorn K, Vink G, Schouten R, Robitzsch A, Rockenschaub P, Doove L, Jolani S, Moreno-Betancur M, White I, Gaffert P, Meinfelder F, Gray B and ArelBundock V: Package ‘mice’. Available at https://cran.rproject.org/web/packages/mice/mice.pdf. Last accessed on 3rd October 2021.
28) Sing T, Sander O, Beerenwinkel N, Lengauer T and Unterthiner T: Package ‘ROCR’. Available at https://cran.r-project.org/web/packages/ROCR/ROCR.pdf. Last accessed on 3rd October 2021.
29) Uemura O, Honda M, Takeshi Matsuyama T, Ishikura K, Hataya H, Yata N, Nagai T, Ikezumi Y, Fujita N, Ito S, Iijima K and Kitagawa T: Age, gender, and body length effects on reference serum creatinine levels determined by an enzymatic method in Japanese children: A multicenter study .Clin Exp Nephrol.2011; 15(5): 694–699.
30) Tsurusawa M, Gosho M, Mori T, Mitsui T, Sunami S, Kobayashi R, Fukano R, Tanaka F, Fujita N, Inada H, Koh K, Takimoto T, Saito A, Fujimoto J, Nakazawa A and Horibe K: Lymphoma committee of the Japanese Pediatric Leukemia/lymphoma Study Group. Statistical analysis of the relationship between plasma methotrexate concentration and toxicity in high-dose methotrexate therapy of childhood nonHodgkin lymphoma.Pediatr Blood Cancer. 2015; 62(2): 279-284.
31) Sterba J, Dusek L, Demlova R and Valik D: Pretreatment plasma folate modulates the pharmacodynamic effect of high-dose methotrexate in children with acute lymphoblastic leukemia and non-Hodgkin lymphoma: "folate overrescue" concept revisited. Clin Chem. 2006; 52(4): 692-700.
32) Becker ML, Rosé CD, Cron RQ, Sherry DD, Bilker WB and Lautenbach E: Effectiveness and toxicity of methotrexate in juvenile idiopathic arthritis: Comparison of 2 initial dosing regimens. J Rheumatol. 2010; 37(4) 870–875.
33) Ottaviani G and Jaffe N: The epidemiology of osteosarcoma. Cancer Treat Res. 2009; 152: 3-13.
34) Joerger M, Huitema ADR, Krähenbühl S, Schellens JHM, Cerny T, Reni M, Zucca E, Cavalli F and Ferreri AJM: Methotrexate area under the curve is an important outcome predictor in patients with primary CNS lymphoma: A pharmacokinetic-pharmacodynamic analysis from the IELSG no. 20 trial. Br J Cancer. 2010; 102(4): 673-677.
35) Fukuhara K, Ikawa K, Morikawa N and Kumagai K: Population pharmacokinetics of highdose methotrexate in Japanese adult patients with malignancies: a concurrent analysis of the serum and urine concentration data. J Clin Pharm Ther. 2008; 33(6): 677-684.
36) Shen DD and Azarnoff DL: Clinical pharmacokinetics of methotrexate. Clin Pharmacokinet. 1978; 3(1): 1-13.
37) Xu WQ, Zhang LY, Chen XY, Pan BH, Mao JQ, Song H, Li JY and Tang YM: Serum creatinine and creatinine clearance for predicting plasma methotrexate concentrations after high-dose methotrexate chemotherapy for the treatment for childhood lymphoblastic malignancies. Cancer Chemother Pharmacol. 2014; 73(1): 79-86.
38) Graf N, Winkler K, Betlemovic M, Fuchs N and Bode U: Methotrexate pharmacokinetics and prognosis in osteosarcoma. J Clin Oncol. 1994; 12(7): 1443–1451.
39) Sandhu R, Lal H, Kundu ZS and Kharb S: Serum fluoride and sialic acid levels in osteosarcoma. Biol Trace Elem Res. 2011; 144(1-3): 1–5.
40) Al-Khan AA, al Balushi NR, Richardson SJ and Danks JA: Roles of parathyroid hormonerelated protein (pthrp) and its receptor (pthr1) in normal and tumor tissues: focus on their roles in osteosarcoma. Front Vet Sci. 2021; 8: 637614.
41) Baird GS: Ionized calcium. Clinica Chimica Acta. 2011; 412(9-10) 696–701.
42) Datta M, Savage P, Lovato J and Schwartz GG: Serum calcium, albumin and tumor stage in cutaneous malignant melanoma. Future Oncology. 2016; 12(19): 2205–2214.
43) Katarina T: Physical activity in the prevention and amelioration of osteoporosis in women: interaction of mechanical, hormonal and dietary factors. Sports medicine.2005; 35(9), 779-830.
44) Koke W, Campos-Obando N, Eerden B, Rijke Y, Ikram M, Uitterlinden A, Leeuwen J, Zillilens M: Age-dependent sex differences in calcium and phosphate homeostasis. Endocr connec.2021: 10(3), 273-282.
45) Ramsey LB, Panetta JC, Smith C, Yang W, Fan Y, Winick NJ, Martin PL, Cheng C, Devidas M, Pui CH, Evans WE, Hunger SP, Loh M and Relling MV: Genomewide study of methotrexate clearance replicates SLCO1B1. Blood. 2013; 121(6): 898–904.
46) Cegieła U, Sliwiński L, Kaczmarczyk-Sedlak I and Folwarczna J: In vivo effects of highdose methotrexate on bone remodeling in rats. Free Radic Res. 2018; 52(6): 698-711.
47) De S, Kundu S, Chatterjee U, Chattopadhyay S and Chatterjee M: Allylpyrocatechol attenuates methotrexate-induced hepatotoxicity in a collagen-induced model of arthritis. Ann Pharmacother.2020; 54(1): 29-35.
48) Bacci G, Ferrari S, Bertoni F, Ruggieri P, Picci P, Longhi A, Casadei R, Fabbri N, Forni C, Versari M and Campanacci M: Long-term outcome for patients with nonmetastatic osteosarcoma of the extremity treated at the istituto ortopedico rizzoli according to the istituto ortopedico rizzoli/osteosarcoma-2 protocol: an updated report. J Clin Oncol. 2000; 18(24): 4016-4027.
49) Winkler K, Beron G, Delling G, Heise U, Kabisch H, Purfürst C, Berger J, Ritter J, Jürgens H and Gerein V: Neoadjuvant chemotherapy of osteosarcoma: results of a randomized cooperative trial (COSS-82) with salvage chemotherapy based on histological tumor response. J Clin Oncol.1998; 6(2): 329-337.
50) Anroop B. Shery Jacob. A simple practice guide for dose conversion between animals and human. Journal of basic and clinical pharmacy. 2016; 7(2):27-31.
51) Bremnes RM, Slørdal L, Wist E and Aarbakke J: Dosedependent pharmacokinetics of methotrexate and 7- hydroxymethotrexate in the rat in vivo. Cancer Res.1989; 49(22):6359- 6364.
52) Wang Z, Okamoto M, Kurosaki Y, Nakayama T and Kimura T: Pharmacokinetics of glycyrrhizin in rats with D-galactosamineinduced hepatic disease. Biol Pharm Bull.1996; 19(6): 901-904.
53) lshizaki J, Nakano C, Kitagawa K, Suga Y and Sai Y: A previously unknown drug-drug interaction is suspected in delayed elimination of plasma methotrexate in high-dose methotrexate therapy. Pharmacol Rep. 2005; 57(4): 504-514.
54) VanWert AL and Sweet DH: Impaired clearance of methotrexate in organic anion transporter 3 (Slc22a8) knockout mice: a gender specific impact of reduced folates. Pharm Res. 2008; 25(2): 453-462.
55) Vlaming ML, Pala Z, van Esch A, Wagenaar E, de Waart DR, van de Wetering K, van der Kruijssen CM, Oude Elferink RP, van Tellingen O and Schinkel AH: Functionally overlapping roles of Abcg2 (Bcrp1) and Abcc2 (Mrp2) in the elimination of methotrexate and its main toxic metabolite 7-hydroxymethotrexate in vivo. Clin Cancer Res. 2009; 15(9): 3084-3093.
56) Schumacher GE, Madden T and Eaton VE: Methotrexate. In: Therapeutic Drug Monitoring. Schumacher GE (eds.). Connecticut, Appleton & Lange, pp. 527-552, 1995.
57) Bremnes RM, Slørdal L, Wist E, Aarbakke J: Formation and Elimination of 7- Hydroxymethotrexate in the Rat in Vivo after Methotrexate Administration. Cancer Res, 1989; 49(9), 2460-2464.
58) Abelson HT, Fosburg MT, Beardsley GP, Goorin AM, Gorka C, Link M and Link D: Methotrexate-induced renal impairment: clinical studies and rescue from systemic toxicity with high-dose leucovorin and thymidine. J Clin Oncol. 1983; 1(3): 208-216.
59) Exadaktylos P, Reiss T, Schobess R, Hommann M, Höhne S and Beck A: Acute hepatotoxicity with intermediate-dose methotrexate in children with leukemia and nonHodgkin’s lymphoma. Klin Padiatr. 1994; 206(4): 315-318.
60) Hegyi M, Gulácsi A, Cságoly E, Csordás K, Eipel OT, Erdélyi DJ, Müller J, Nemes K, Lautner-Csorba O and Kovács GT: Clinical relations of methotrexate pharmacokinetics in the treatment for pediatric osteosarcoma. J Cancer Res J Clin Oncol. 2012; 138(10): 1697- 1702.
61) Ishida S, Sakiya Y, Ichikawa T, Awazu S. Pharmacokinetics of Glycyrrhetic Acid, a Major Metabolite of Glycyrrhizin, in Rats. Chem. Pharm. Bull. 1989; 37(9), 2509-2513.
62) Tung-Hu Tsai, Jyh-Fei Liao, Andrew Yau-Chik Shum, Chieh-Fu Chen. Pharmacokinetics of Glycyrrhizin after Intravenous Administration to Rats. Journal of Pharmaceutical Sciences. 1992; 81(9):961-963.
63) 中野直子, 加藤弘已, 鈴木英彦, 中尾院英, 矢野三郎, 金岡又雄. グリチルレチン酸 およびグリチルリチンの酵素免疫測定法 (第2報), 血中グリチルレチン酸, グリチ ルリチンの測定, 薬理と治療. 1980; 8(11): 4171-4174.